Skip to main content
. 2017 Mar 16;8(18):29963–29975. doi: 10.18632/oncotarget.16265

Figure 7. Analysis of MMS sensitivity and PARP inhibition on the radiosensitivity of HPV-negative and HPV-positive OPSCC cells.

Figure 7

(A) Clonogenic survival of OPSCC cells was analysed following treatment with increasing doses of MMS (0–2 mM). Shown is the surviving fraction with standard errors from at least three independent experiments. (B) Whole cell extracts from OPSCC cells were prepared and analysed by 10 % SDS-PAGE and immunoblotting with either MPG or actin antibodies. Clonogenic survival of (C) HPV-positive OPSCC cells or (D) HPV-negative OPSCC cells was analysed following treatment with increasing doses of IR (0–4 Gy) in the absence and presence of the PARP inhibitor olaparib (0.1 μM). Shown is the surviving fraction with standard errors from at least three independent experiments.